ArticleInfection2026
Persistent candidemia matters: risk factors and clinical outcomes in a retrospective matched cohort study.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectivesPersistent candidemia remains incompletely understood, with inconsistent definitions and conflicting evidence on outcomes. We aimed to identify factors associated with persistent candidemia and to assess its impact on complications and 30-day mortality in a single-centre cohort.
methodsWe conducted a retrospective matched cohort study including patients aged ≥ 14 years with at least one positive peripheral blood culture for Candida species (September 2014-September 2024) at a 900-bed tertiary hospital in Valencia, Spain. Persistent candidemia was defined as isolation of the same Candida species from blood cultures obtained ≥ 5 days after initiation of appropriate antifungal therapy. A total of 105 patients with persistent candidemia were compared with 105 with non-persistent candidemia, matched by Charlson comorbidity index. Multivariable logistic regression identified factors independently associated with persistence and 30-day mortality.
resultsPersistent candidemia was identified in 105/515 (20.4%) patients with follow-up cultures. Patients with persistent candidemia were younger (59.3 vs. 66.0 years, p = 0.02) and had higher Candida scores (2 [IQR 1-3] vs. 2 [1-2], p = 0.03). Persistent candidemia was associated with central venous catheter presence (80% vs. 65.7%, p = 0.03), parenteral nutrition (61.9% vs. 46.7%, p = 0.04), and ICU-acquired candidemia (55.2% vs. 37.1%, p = 0.01). Early catheter removal within 48 h was less frequent (27.2% vs. 56.8%, p < 0.01) and independently associated with a reduced risk of persistence (aOR 0.20; 95% CI 0.09-0.42). Thirty-day mortality was higher in patients with persistent candidemia (29.5% vs. 16.2%, p = 0.03). After adjustment, persistent candidemia (aOR 2.10; 95% CI 1.03-4.26) and ICU-acquired candidemia (aOR 3.38; 95% CI 1.57-7.29) remained independently associated with increased 30-day mortality.
conclusionsPersistent candidemia occurred in one in five patients and was independently associated with increased 30-day mortality. Early catheter removal emerged as the only independent protective factor, underscoring the importance of prompt source control and systematic follow-up blood cultures in the management of candidemia.
Indexed as
Identifiers
42696247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.